Gene signatures of drug resistance predict patient survival in colorectal cancer

Pharmacogenomics Journal

Volumn 15, Issue 2, 2015, Pages 135-143

  Zheng, Y ^a,b   Zhou, J ^c   Tong, Y ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF ARIZONA   (United States)

^d XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE ONTOLOGY; GENE SIGNATURE; GENETIC PARAMETERS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL PREDICTION; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; HCT116 CELL LINE; MORTALITY; SURVIVAL; SURVIVAL RATE; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HCT116 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84925444323     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.45     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 155-166.
3. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12: 89.
4. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45: 872-877.
5. Jensen NF, Smith DH, Nygård SB, Rømer MU, Nielsen KV, Brünner N. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 2012; 47: 340-355.
6. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G et al. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006; 7: R19.
7. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011; 18: 18-25.
8. Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013; 71: 265-272.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
11. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S et al. Pharmaco-genomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006; 66: 2765-2777.
12. Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S et al. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Mol Cancer Ther 2012; 11: 1724-1734.
13. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 2009; 15: 7642-7651.
14. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138: 958-968.
15. Tong Y, Zhou J, Mizutani J, Fukuoka H, Ren SG, Gutierrez-Hartmann A et al. CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endo-crinol 2011; 25: 1880-1891.
16. Peterson ML, Ma C, Spear BT. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin Cancer Biol 2011; 21: 21-27.
17. van Abel D, Hölzel DR, Jain S, Lun FM, Zheng YW, Chen EZ et al. SFRS7-mediated splicing of tau exon 10 is directly regulated by STOX1A in glial cells. PLoS One 2011; 6: e21994.
18. Al-Bassam J, Chang F. Regulation of microtubule dynamics by TOG-domain proteins XMAP215/Dis1 and CLASP. Trends Cell Biol 2011; 21: 604-614.
19. Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M et al. Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J Cancer Res Clin Oncol 2010; 136: 465-473.
20. Chiang MH, Chen LF, Chen H. Ubiquitin-conjugating enzyme UBE2D2 is responsible for FBXW2 (F-box and WD repeat domain containing 2)-mediated human GCM1 (glial cell missing homolog 1) ubiquitination and degradation. Biol Reprod 2008; 79: 914-920.
21. Bertino JR, Waud WR, Parker WB, Lubin M et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther 2011; 11: 627-632.
22. Kunzelmann K, Schreiber R, Kmit A, Jantarajit W, Martins JR, Faria D et al. Expression and function of epithelial anoctamins. Exp Physiol 2012; 97: 184-192.
23. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
24. Martinez-Cardus A, Martinez-Balibrea E, Bandrés E, Malumbres R, Ginés A, Manzano JL et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 2009; 8: 194-202.
25. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13: 1841-1851.
26. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011; 105: 1759-1767.
27. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008; 68: 5380-5389.
28. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008; 7: 670-678.
29. Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G et al. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human col-orectal cancer cell lines. Stem Cells Transl Med 2012; 1: 592-603.
30. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010; 292: 73-79.
31. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001; 62: 207-212.
32. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117: 3409-3420.
33. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277: 757-763.
34. Cain JW, Hauptschein RS, Stewart JK, Bagci T, Sahagian GG, Jay DG. Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res 2011; 9: 637-647.
35. Chong K, Subramanian A, Sharma A, Mokbel K. Measuring IGF-1, ER-alpha and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Anticancer Res 2011; 31: 23-32.
36. Skinner MA, Lackey KE, Freemerman AJ. RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells. Anticancer Res 2008; 28: 2019-2025.
37. Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 2010; 285: 21446-21457.
38. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013; 27: 702-710.
39. Flint MS, Kim G, Hood BL, Bateman NW, Stewart NA, Conrads TP. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway. Psychoneuroendocrinology 2009; 34: 1533-1541.
40. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and che-motherapeutic resistance. Drug Resist Updat 2002; 5: 234-248.
41. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
42. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90-97.
43. Joyce T, Oikonomou E, Kosmidou V, Makrodouli E, Bantounas I, Avlonitis S et al. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. Curr Cancer Drug Targets 2012; 12: 873-898.
44. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012; 12: 260.
45. Levine EA, Blazer DG 3rd, Kim MK, Shen P, Stewart JH 4th, Guy Cet al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 2012; 214: 599-606.
46. Chen X, Halberg RB, Burch RP, Dove WF. Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol 2008; 39: 283-294.